Scholarlink

<p>In response to a variety of oncogenic processes, <i>Psoralea corylifolia</i> Linn. (<i>P. corylifolia</i>), a medicinal plant with a rich history in traditional Chinese medicine, demonstrates diverse therapeutic potential, particularly in oncology. This review explores the anti-cancer effects of <i>P. corylifolia</i>, focusing on its bioactive compounds, such as psoralen, bakuchiol, psoralidin and astragalin, etc. These compounds target critical cancer hallmarks, including sustaining proliferative signaling, resisting cell death, and activating invasion and metastasis. Mechanistically, compounds like psorachromene and psoralidin inhibit key pathways, such as EGFR signaling, and induces apoptosis via ROS-mediated DNA damage, mitochondrial dysfunction, and caspase and JNK activation. Additionally, astragalin exhibits anti-metastatic potential by downregulating matrix metalloproteinases (MMPs) and disrupting cytoskeletal dynamics. The research community has recently begun to deduce the therapeutic potential of <i>P. corylifolia</i> from its ability to modulate these key signaling pathways. In manipulating these pathways, compounds like psoralen and psorachromene serve as deterministic players in controlling tumor fate. Understanding the mechanistic underpinning of their pro-apoptotic and anti-metastatic pathways might elucidate novel therapeutic targets, providing opportunities to integrate <i>P. corylifolia</i> in augmenting the efficacy of conventional treatments to inhibit tumor progression and achieve metastatic control. Accordingly, this review highlights the promise of <i>P. corylifolia</i> as a multifaceted agent in cancer therapy. Summarizing and clustering findings into cancer hallmarks and tissue contexts, this study underscores its potential in clinical application while emphasizing the need for standardization, toxicity profiling, and large-scale clinical trials to validate its safety and efficacy.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Anti-cancer effects of Psoralea corylifolia: insights into cancer hallmarks

  • 期刊论文

  • 发表日期：

    2025年7月14日

查看全文
  • Pin-Rong Chen,
  • Tz-Syuan Su,
  • Kun-Che Chang,
  • Chien-Chih Chiu,
  • Shu-Pin Huang,
  • Hsin-Chih Yeh,
  • Shu-Chi Wang,
  • Chia-Yang Li

摘要

In response to a variety of oncogenic processes, Psoralea corylifolia Linn. (P. corylifolia), a medicinal plant with a rich history in traditional Chinese medicine, demonstrates diverse therapeutic potential, particularly in oncology. This review explores the anti-cancer effects of P. corylifolia, focusing on its bioactive compounds, such as psoralen, bakuchiol, psoralidin and astragalin, etc. These compounds target critical cancer hallmarks, including sustaining proliferative signaling, resisting cell death, and activating invasion and metastasis. Mechanistically, compounds like psorachromene and psoralidin inhibit key pathways, such as EGFR signaling, and induces apoptosis via ROS-mediated DNA damage, mitochondrial dysfunction, and caspase and JNK activation. Additionally, astragalin exhibits anti-metastatic potential by downregulating matrix metalloproteinases (MMPs) and disrupting cytoskeletal dynamics. The research community has recently begun to deduce the therapeutic potential of P. corylifolia from its ability to modulate these key signaling pathways. In manipulating these pathways, compounds like psoralen and psorachromene serve as deterministic players in controlling tumor fate. Understanding the mechanistic underpinning of their pro-apoptotic and anti-metastatic pathways might elucidate novel therapeutic targets, providing opportunities to integrate P. corylifolia in augmenting the efficacy of conventional treatments to inhibit tumor progression and achieve metastatic control. Accordingly, this review highlights the promise of P. corylifolia as a multifaceted agent in cancer therapy. Summarizing and clustering findings into cancer hallmarks and tissue contexts, this study underscores its potential in clinical application while emphasizing the need for standardization, toxicity profiling, and large-scale clinical trials to validate its safety and efficacy.

Graphical abstract